T he goal of transplantation is to induce donor-specific tolerance in the absence of pharmacologic immunosuppression (1, 2) . One approach to successfully achieving long-term graft survival in murine cardiac allograft models is with anti-CD154 (MR1) mAb therapy (3) (4) (5) (6) (7) (8) . Blocking CD40-CD154 interactions abrogates both naive B cell responses and T cell priming (9) . Despite success of achieving long-term graft survival in murine models using anti-CD154 and tolerance induction in rodent models, it has proven difficult to establish allograft tolerance in larger animals, including nonhuman primates and humans (10, 11) . One hypothesis is that higher frequencies of memory alloreactive T lymphocytes are present in pretransplanted nonhuman primates and humans, and that these memory T cells have different activation requirements compared with naive cells (12) .
Memory alloreactive T cells and B cells can be generated in patients as a result of prior pregnancies, blood transfusions, transplantations, autoreactivity, or infections (13) (14) (15) . The ability of memory T cells to negatively impact graft outcome in both human and murine models is well characterized (12, 16 -20) . However, the contribution of memory B cells, isolated from the effects of memory T cells, in overcoming anti-CD154-mediated graft rejection has not yet been clarified.
Memory B cells are generated through a series of events. Upon activation, naive B cells mature and migrate either to the red pulp or marginal zone, where they differentiate into short-lived plasma cells, or to the follicles, where they undergo affinity maturation and isotype switching to differentiate into long-lived plasma cells or memory B cells (21) . Long-lived Ab-secreting cells continuously secrete Abs, while memory B cells secrete Ab upon reactivation with Ag (22) . Memory B cells have a lower activation threshold compared with naive B cells and, under some circumstances, may not rely on cognate T cell help for reactivation and maturation into Ab-secreting cells (23) . Although it has been difficult to identify a marker solely tracking murine memory B cells due to their heterogeneity, CD73, CD80, and CD86 have been shown to be expressed on memory B cells (24, 25) .
Most patients with a sensitized humoral response to alloantigens can be readily identified by the presence of high titers of anti-donor Abs, which can be detected during cross-match testing. It is also possible that some sensitized patients harbor memory B cells, but not long-lived plasma cells, and therefore have low-to-undetectable titers of donor-reactive Abs. We reason that for both groups of patients it is important to define the effects of memory B cells, as well as preexisting alloantibodies, in the prevention of long-term graft acceptance. We hypothesize that memory B cells and alloantibodies may prevent the induction of long-term graft acceptance and contribute to graft rejection by three possible mechanisms. The first involves alloantibodies binding to donor vascular endothelium, resulting in Ab-mediated vascular rejection via complement activation and ligation of FcRs (26) leading to graft thrombosis. Clinical studies by Rifle et al. and others have demonstrated that the presence of high titers of preformed alloantibodies in transplant recipients correlates with complement deposition and poor graft survival (27, 28) . Rodent studies have demonstrated that the transfer of subthreshold doses of complement-activating Abs into B cell-deficient recipients (C57BL/6 Ig Ϫ/Ϫ ) receiving B10.A (H-2 a ) cardiac allografts restored acute humoral rejection, while the inhibition of the terminal complement activation with anti-C5 mAbs prevented Ab-mediated rejection, leading to long-term graft survival and accommodation (29) .
Second, memory B cells may be able to contribute to allograft rejection through their ability to serve as APCs and directly activate allospecific T cells. Recent studies by Naji and colleagues revealed that allograft rejection is impaired in recipients with MHC class II-deficient B cells, which are unable to engage in cognate interactions with CD4 ϩ T cells (30) . These observations support the notion that B cells may be critical APCs for stimulating alloreactive CD4
ϩ T cells and the production of alloantibodies in vivo, although those studies did not definitively determine whether cognate B-T cell interactions or secreted alloantibodies were directly responsible for optimum T cell activation.
A third mechanism by which alloantibodies can contribute to graft rejection is by the formation of Ab-alloantigen immune complexes, which leads to the enhancement of cell-mediated rejection responses. Immune complexes can engage activating FcRs and complement receptors to induce the maturation of APCs, which can ultimately lead to enhanced CD4 and CD8 T cell activation (31, 32) . However, there has been no direct demonstration for this process in the context of allograft transplantation and rejection.
To define the impact of functional memory B cells and alloantibodies on the induction of transplantation tolerance, we developed a murine heart transplant model that specifically generated allospecific functional memory B cells without generating allospecific memory T cells. Using this model, we report that the presence of memory 3-83 B cells facilitated the activation and proliferation of naive allospecific T cells, leading to acute allograft rejection in anti-CD154-treated recipients. Transfer of B cells together with sera from presensitized recipients or purified allo-specific mAbs, but not T cells, prevented the induction of long-term graft survival by anti-CD154. Thus, recipients harboring memory alloreactive B cells and/or preformed alloantibodies can resist the immunosuppressive and tolerogenic effects of anti-CD154 by facilitating the activation of alloreactive CD4 ϩ T cells.
Materials and Methods

Animals
Male and female C57BL/6 (H-2 b ), BALB/c (H-2 d ), and C3H (H-2 K ) inbred mice, aged 7-9 wk, were purchased from The Jackson Laboratory and the National Cancer Institute, Frederick Cancer Research and Development Center (Frederick, MD). Act-OVA transgenic (Tg) C57BL/6 males and females were purchased from The Jackson Laboratory. Female C57BL/ 6Ji-K btm1 N12 mice (K b -deficient mice) were purchased from Taconic at 6 wk of age. Male and female B10.M-H2 f H2-T18 a? /SnJ (B10.F) mice, aged 6 -8 wk, were obtained from The Jackson Laboratory. 3-83 Igi knockin mice were obtained as a generous gift from Dr. Roberta Pelanda (National Jewish Medical and Research Center and University of Colorado Health Sciences Center), while Rag Ϫ/Ϫ BALB/c mice were a generous gift from Dr. Yang Xin Fu (The University of Chicago). All animals were maintained and bred in the pathogen-free Carlson Barrier animal facility at The University of Chicago. The use of animals for these studies has been reviewed and approved by the Institutional Animal Care and Use Committee at The University of Chicago.
Antibodies
Anti-3-83 idiotypic mAbs were generated from the 54.1 hybridoma, a generous gift of Dr. Roberta Pelanda. Biotinylation and FITC conjugation of 54.1 was performed by the Immunology Applications Core Facility at The University of Chicago (Chicago, IL). 3-83 IgG2a Abs were generated from a 3-83 hybridoma (American Type Culture Collection), and 3-83 IgG2a was purified using an immobilized protein G column. The purified Abs were dialyzed in PBS for 48 h at 4°C.
Heterotopic heart transplantation
Heart transplantation was performed as previously described (33) . Briefly, transplantation of vascularized murine cardiac allografts was performed under a mixture of ketamine (100 mg/kg) and xylazine (5 mg/kg). Briefly, the donor aorta and pulmonary artery were anastomosed to the recipient abdominal aorta and inferior vena cava, respectively. Graft function was monitored by abdominal palpation daily until rejection, which was defined as total cessation of contractions and was confirmed by direct visualization of the allograft.
Costimulatory blockade regimen
Donor-specific transfusion comprised of donor-derived splenocytes was prepared by passing whole splenocyte preparations through a sterile 0.2-m filter and resuspending in PBS. Donor spleen cells (2 ϫ 10 7 ) were injected i.v. at the time of transplantation. The anti-CD154 (MR1) hybridoma was a generous gift from Dr. Keith Bishop (The University of Michigan, Ann Arbor, MI), and anti-CD154 mAbs were purified from proteinfree hybridoma medium (Invitrogen) using 45% ammonium sulfate precipitation and dialyzed for 48 h in PBS. On days 0, 7, and 14 posttransplantation, 1 mg of anti-CD154 mAbs/mouse was injected i.v.. The human CTLA4Ig (Bristol-Myers Squibb) was administered on days 0, 2, 4, and 6 of transplantation (0.5 mg/mouse) by i.p. injection.
Lymphocyte isolation
B cells were isolated by negative selection using a commercially available murine CD19 ϩ isolation kit from Miltenyi Biotec. T cells were isolated by negative selection using a commercially available murine CD3 ϩ T cell enrichment kit also from Miltenyi Biotec.
Flow cytometry
PE-conjugated anti-mouse DO11.10 TCR (KJ126), allophycocyanin-conjugated anti-mouse CD4, propidium iodide, PerCP-conjugated anti-mouse CD19, biotin-conjugated anti-mouse IgM, allophycocyanin-conjugated strepavidin, FITC-conjugated anti-mouse IgG, and biotin-conjugated antimouse IgG2a Abs were purchased from BD Biosciences. Anti-mouse 54.1 Ab was conjugated to FITC by the Immunology Applications Core Facility at The University of Chicago (Chicago, IL). PE-conjugated K d tetramers (presenting the nonviral peptide KYNKANVFL), PE-conjugated K k tetramers (presenting the polyoma virus peptide SEFLLEKRI), and PE-conjugated K b tetramers (presenting the herpesvirus peptide SSIEFARL) were purchased from the National Institutes of Health Tetramer Facility (Emory University, Atlanta, GA). Spleen cells from the heart graft recipients or naive mice were labeled on ice for 45 min with appropriate Ab, followed by two washes in 2% FBS/PBS 0.01% sodium azide (FACS buffer). The labeled cells were resuspended in FACS buffer and analyzed on the FACScan or FACSCanto benchtop analyzers (BD Biosciences) using FlowJo flow cytometry analysis software (Tree Star).
Adoptive transfer experiments
At the time of heterotopic heart transplantation naive BALB/c female or male mice were adoptively transferred with either memory B cells (1.7-2.0 ϫ 10 7 ) or C3H-primed T cells (20 -25 ϫ 10 6 ) along with 1 mg of anti-CD154 treatment, both via tail vein injection, immediately posttransplantation. Graft function was monitored by daily abdominal palpation. In other experiments, naive BALB/c mice were adoptively transferred with CFSE (5 M)-labeled D011.10 TCR Tg CD4 ϩ T cells (10 6 ) along with 1 mg of anti-CD154, both injected via tail vein, at the time of transplantation. Animals were sacrificed on day 5 for analysis of CFSE dilution using flow cytometry.
ELISPOT assays
IFN-␥ ELISPOT. Briefly, ELISPOT plates (Millipore) were coated overnight with anti-IFN-␥ capture Ab (BD Biosciences) and then blocked with sterile 10% FBS in PBS (PBST). Responder T cells were harvested from transplant recipients, and T cells were purified by negative selection using a mouse Pan T cell isolation kit (Miltenyi Biotec). Syngeneic (BALB/c), allogeneic (C57BL/6), and third-party (C3H) splenocyte preparations were gamma-irradiated (1200 rad for 10 min) and used as stimulators. Responders were plated at 1 ϫ 10 6 /well, with or without anti-CD3 (clone 2C11), C3H, BALB/c, or C57BL/6 stimulators (0.4 ϫ 10 6 /well), and then incubated at 37°C, 5% CO 2 overnight. Biotinylated anti-IFN-␥ detection Ab (BD Biosciences) was added followed by HRP-conjugated anti-biotin (BD Biosciences). Plates were developed as previously described, and the resulting spots were analyzed using an ImmunoSpot series 1 analyzer (Cellular Technology).
Idiotypic ELISPOT. Briefly, ELISPOT plates (Millipore) were coated with 54.1 Ab. Splenocyte preparations were derived from transplant recipients or naive controls. Whole splenocytes were plated in 10% FBS/DMEM at concentrations of 1 ϫ 10 6 /well, 0.75 ϫ 10 6 /well, 0.5 ϫ 10 6 /well, and 0.25 ϫ 10 6 /well and then incubated overnight at 37°C, 5% CO 2 . Biotinconjugated anti-mouse IgG Fab or anti-mouse IgM (BD Biosciences) were added followed by HRP-conjugated streptavidin (BD Biosciences), and the plates were developed and analyzed using an ImmunoSpot series 1 analyzer.
Immunofluorescence staining of tissue sections
Spleens and hearts were preserved in OCT medium (Sakura Finetek), immediately submerged in liquid nitrogen for 1 h, and subsequently transferred to Ϫ80°C. Five-micrometer cryostat sections were fixed with 100% acetone, blocked using 10% normal goat serum, and then incubated with PE-conjugated anti-mouse CD4 Ab, PE-conjugated anti-mouse CD8 Ab (BD Biosciences), PE-conjugated tetramers (National Institutes of Health Tetramer Facility), or with H&E staining.
Statistical analysis
Statistical analysis to determine differences between groups for recall immune responses were performed using Student's t test for equal or unequal variances using Prism 4 for Macintosh (GraphPad). Kaplan-Meier survival analysis was performed to determine significant differences in median graft survival between groups. A value of p Ͻ 0.05 was considered statistically significant.
Results
Characterization of dual specific memory B cells
The 3-83 BCR has dual alloreactive specificity for H-2K
k and H-2K b , and Ͼ95% percent of the B cells in the 3-83 Igi mouse express the 3-83 BCR (34, 35) . The 3-83 B cells can be traced by flow cytometry or immunohistochemistry using the 3-83-idiotypic Ab, while confirmation of 3-83 B cell dual specificity was achieved by performing flow cytometry and immunofluorescene staining of spleen sections with Abs to mucosal addressin cell adhesion molecule 1 (MadCAM-1) and either K k , K b , or K d tetramers, respectively ( Fig. 1, a and b) . Notably, MHC class I tetramers have been used for the tracking of Ag-specific CD8 ϩ T cells, in which the peptide Ag presented by the class I molecule determines recognition by the TCR. However, recognition of 3-83 B cells by MHC class I K k and K b tetramers is not significantly affected by the peptide Ag being presented.
Following sensitization with C3H cardiac allografts, we waited 60 days for the generation of functional memory B cells. At this time, we observed that presensitized 3-83 Igi allograft recipients harbored a population of CD19 ϩ IgG ϩ B cells that was increased 2.5-fold compared with naive 3-83 Igi mice, thus demonstrating that presensitized 3-83 Igi mice had a significantly increased frequency of Ag-experienced B cells ( Fig. 1c ; p ϭ 0.0027). To test the specificity of the primed T cell response, we quantified the frequency of C3H-and C57BL/6-reactive T cells at 60 days after receiving C3H hearts, but before receiving the C57BL/6 hearts, using an IFN-␥ ELISPOT assay. We observed a significantly increased frequency of primed, IFN-␥-producing T cells that were C3H-reactive compared with naive 3-83 Igi recipients ( Fig. 2a ; p ϭ 0.0019). We also noted a low frequency of C57BL/6-reactive IFN-␥-producing T cells from presensitized mice, but this level was not significantly different from the naive nontransplanted controls ( Fig. 2a ; p ϭ 0.3163). Thus, we reasoned that a challenge of these presensitized 3-83 Igi mice with a C57BL/6 heart permitted us to focus on the effects of functional memory B cells with minimal contribution from memory C57BL/6-reactive T cells.
We first tested the susceptibility of the C3H-sensitized 3-83 Igi mice to tolerance induction. 3-83 Igi mice, sensitized with C3H hearts for at least 60 days, received a C57BL/6 graft and were treated with anti-CD154. This anti-CD154 treatment regimen induced long-term graft survival (Ͼ60 days) in naive 3-83 Igi recipients ( Fig. 2b) , and in the absence of anti-CD154 treatment naive 3-83 recipients rejected C57BL/6 grafts in 8 -10 days. Presensitized 3-83 Igi recipients treated with anti-CD154 acutely rejected the second C57BL/6 graft (mean survival time (MST), 3 10 days; p ϭ 0.0012). We also observed rejection of C57BL/6 cardiac allografts in presensitized 3-83 recipients treated with a more robust tolerance-inducing protocol of anti-CD154 plus donor-specific spleen cell transfusion (DST; Fig. 2b ).
Immunohistochemical analysis revealed heightened numbers of CD4 ϩ and CD8 ϩ T cells infiltrating the rejected allografts of presensitized 3-83 Igi recipients treated with anti-CD154 (Fig. 3a) compared with nonrejected C57BL/6 grafts in presensitized wildtype BALB/c recipients that were also treated with anti-CD154. Conversely, cellular infiltration was barely detectable in naive 3-83 Igi recipients that received anti-CD154. These findings are consistent with the conclusion that the presence of functional memory 3-83 B cells prevented anti-CD154-mediated allograft acceptance by facilitating the CD154-independent activation of naive alloreactive T cells. An alternative conclusion is that the small population of C57BL/6-reactive memory T cells, generated during sensitization with the first C3H heart, mediated the anti-CD154-resistant rejection independently of functional memory B cells. A third possibility is that the low frequency of C57BL/6-reactive memory T cells synergized with the functional memory 3-83 B cells to facilitate anti-CD154-resistant allograft rejection. 
Memory 3-83 B cells are necessary for anti-CD154 resistant rejection
To test whether the rejection of C57BL/6 grafts in presensitized 3-83 Igi recipients treated with anti-CD154 was dependent on functional memory 3-83 B cells, and not due solely to cross-reactive anti-C57BL/6 memory T cell populations, we performed the next series of experiments using wild-type BALB/c mice with the same background as the 3-83 Igi mice, but lacking dual-specific 3-83 B cells, and these mice were sensitized with C3H hearts. Sixty days after priming with a C3H heart, a C57BL/6 heart graft was transplanted and recipients were treated with anti-CD154. In the absence of 3-83 B cells, C3H-sensitized BALB/c recipients were unable to overcome the immunosuppressive effects of anti-CD154 (Fig. 4a) . All of the C57BL/6 heart grafts were accepted for Ͼ60 days posttransplantation, which is comparable to the survival of naive BALB/c recipients harboring C57BL/6 grafts treated with anti-CD154. The acceptance of C57BL/6 grafts in presensitized BALB/c hosts contrasts with the rejection of C57BL/6 grafts in presensitized 3-83 Igi recipients ( p ϭ 0.0031). We concluded that the presence of functional memory dual-specific 3-83 B cells is necessary for acute allograft rejection in presensitized 3-83 Igi recipients treated with anti-CD154, and that C57BL/6 cross-reactive T cells generated in the BALB/c recipients of C3H hearts were unable to induce acute allograft rejection in the presence of anti-CD154. We next tested whether 3-83 B cells had to be reactivated by the engagement of the BCR with K b expressed by C57BL/6 allografts to mediate allograft rejection in the presence of anti-CD154. We challenged C3H-memory 3-83 Igi recipients with C57BL/6 heart grafts that lacked H-2K b expression, which were obtained from H-2K b -deficient C57BL/6 mice (these mice have a compensatory increase in cell surface expression of other MHC class I molecules FIGURE 2. The presence of memory B cells is necessary for graft rejection in anti-CD154-treated memory 3-83 Igi recipients. a, The frequency of IFN-␥-producing cells was measured in naive 3-83 Igi mice (filled bars) and memory 3-83 Igi mice (60 days post-C3H transplant) (white bars) (n ϭ 14 for naive 3-83 Igi; n ϭ 3 for memory 3-83 Igi mice). Splenocytes were restimulated in vitro with irradiated C57BL/6, BALB/C, C3H stimulators, or treated with anti-CD3 or cell culture media as controls. Individual bars represent data from individual mice that received the same treatment. b, Rejection of C57BL/6 grafts in memory 3-83 Igi recipients receiving anti-CD154 (ࡗ) compared with naive 3-83 Igi recipients of C57BL/6 grafts with anti-CD154 (Ⅺ) and untreated 3-83 Igi recipients of C57BL/6 hearts (F). Also, rejection of C57BL/6 grafts in memory 3-83 Igi recipients receiving anti-CD154 and donor-specific transfusion is shown (C57BL/6 splenocytes, OE) (n ϭ 5 naive 3-83 Igi of C57BL/6 grafts with anti-CD154; n ϭ 7 for memory 3-83 Igi of C57BL/6 grafts with anti-CD154; n ϭ 4 for memory 3-83 Igi of C57BL/6 grafts with anti-CD154 and donor-specific transfusion (DST); n ϭ 5 for naive 3-83 Igi of C57BL/6 grafts untreated). FIGURE 3. Cellular infiltration in rejecting hearts from memory 3-83 Igi recipients. a, Heart allografts were removed 14 days posttransplantation in naive 3-83 Igi recipients of C57BL/6 grafts treated with anti-CD154 (n ϭ 7) (left column), memory 3-83 Igi recipients of C57BL/6 hearts treated with anti-CD154 (n ϭ 3) (middle column), and memory BALB/c recipients of C57BL/6 grafts treated with anti-CD154 (n ϭ 4) (right column). Tissue sections were stained with H&E, anti-CD4, or anti-CD8 to detect cellular infiltration (dark brown spots). b, Anti-CD154-resistant, alloantibody-mediated rejection induces cellular infiltration into allografts. Heart allografts were removed 12-14 days posttransplantation in naive 3-83 Igi recipients of C57BL/6 grafts treated with 0.5 mg of 3-83 IgG2a Abs plus anti-CD154 (n ϭ 3) (left column) and naive 3-83 Igi recipients of C57BL/6 hearts treated with isotype control IgG2a and anti-CD154 (n ϭ 3) (right column). Grafts were stained with H&E, anti-CD4, or anti-CD8 to detect cellular infiltration (dark brown spots).
Db, Q7, and Q9; see Ref.
36)). The H-2K
bϪ/Ϫ grafts survived long term in presensitized 3-83 Igi recipients treated with anti-CD154 in contrast to the acute rejection of H-2K bϩ/ϩ C57BL/6 hearts ( Fig.  4b ; p ϭ 0.0031). In contrast, all H-2K bϪ/Ϫ grafts were acutely rejected when transplanted in untreated, naive 3-83 Igi recipients (data not shown). Thus, the lack of acute allograft rejection of H-2K bϪ/Ϫ C57BL/6 grafts in presensitized 3-83 recipients demonstrates that 3-83 B cells require the recognition of H-2K b molecules on the donor graft to facilitate the acute rejection in anti-CD154-treated recipients. Collectively, these findings demonstrate that fully functional memory B cells are necessary for presensitized 3-83 Igi mice to override the tolerogenic effects of anti-CD154 and to elicit allograft rejection.
We also tested whether memory B cells alone are sufficient to mediate graft rejection in anti-CD154-treated recipients, or whether memory T cells are also important. To test the sufficiency of memory B cells, we transferred CD19 ϩ B cells (1.7-2.0 ϫ 10 7 ) from day Ն60 presensitized 3-83 Igi recipients into naive BALB/c recipients that then received a naive C57BL/6 heart and anti-CD154 (Fig. 5a) . As a control, we transferred comparable numbers of CD19 ϩ B cells isolated from naive 3-83 recipients. The CD19 ϩ cells from presensitized 3-83 Igi mice at the time of C57BL/6 allograft transplantation resulted in the rejection of 50% of the grafts (MST, 37 days; p ϭ 0.0468). These data demonstrate that functional memory 3-83 B cells can be sufficient to facilitate the CD154-independent rejection of C57BL/6 allografts in 50% of BALB/c recipients.
We also tested whether non-B cells, including the small population of C57BL/6-reactive T cells generated in 3-83 recipients following sensitization with C3H hearts, were sufficient to mediate the rejection of allografts in anti-CD154-treated presensitized 3-83 Igi recipients. To this end, we transferred CD19-depleted spleen cells (2.0 -2.5 ϫ 10 7 ) into naive BALB/c recipients of C57BL/6 hearts and treated them with anti-CD154. All the C57BL/6 heart grafts survived Ͼ60 days (Fig. 5b) , in contrast to 50% rejection observed in BALB/c recipients that received 1.7-2.0 ϫ 10 7 memory B cells ( p ϭ 0.00468; Fig. 5a ). In contrast, the transfer of similar numbers of non-B cells was sufficient to elicit the rejection of C3H heart grafts in BALB/c recipients treated with anti-CD154 (Fig. 5b) . These adoptive transfer experiments confirm that functional memory 3-83 B cells, and not cross-reactive T cells, are necessary and sufficient to elicit CD154-independent allograft rejection.
The ability of purified B cells from presensitized 3-83 recipients to induce rejection in only 50% of recipients prompted us to test whether both memory B and T cells are necessary for optimal induction of rejection. Thus, spleen cells from presensitized 3-83 recipients, which contained 1.7-2.0 ϫ 10 7 each of B cells and non-B cells, were cotransferred into naive BALB/c recipients of C57BL/6 hearts and treated with anti-CD154 (Fig. 5b) . Comparable rates of rejection as B cells alone were observed, suggesting that memory cross-reactive T cells were not necessary for the ability of memory 3-83 B cells to facilitate anti-CD154-resistant graft rejection ( p ϭ 0.7227).
Alloantibodies can induce acute allograft rejection in anti-CD154-treated recipients
The presence of high titers of alloantibodies is a common feature of presensitized recipients. These alloantibodies are produced by either short-lived or long-lived plasma cells that are generated following sensitization with alloantigen. Additionally, some alloreactive B cells differentiate into long-lived memory cells, which can rapidly differentiate into short-or long-lived plasma cells that secrete alloantibodies upon rechallenge with alloantigen. We observed very low frequencies of IgG-secreting 3-83 B cells in the spleens of naive 3-83 Igi mice, naive 3-83 Igi recipients receiving C57BL/6 hearts and anti-CD154 treatment, and presensitized 3-83 Igi mice at 60 days after receiving C3H hearts (Fig. 6a) . There was a significant increase in the frequency of IgG-secreting 3-83 B cells in presensitized 3-83 Igi recipients that received a C57BL/6 FIGURE 4. 3-83 B cells are necessary and must recognize allo-MHC molecules to overcome the immunosuppressive effects of anti-CD154. a, Longterm graft survival of memory BALB/c recipients of C57BL/6 heart grafts with anti-CD154 (n ϭ 4) (*) and naive 3-83 Igi recipients of C57BL/6 hearts with anti-CD154 (n ϭ 5) (Ⅺ) compared with rejecting memory 3-83 Igi recipients of C57BL/6 heart grafts with anti-CD154 (n ϭ 7) (ࡗ). b, Long-term graft survival of H-2Kb Ϫ/Ϫ C57BL/6 heart grafts in memory 3-83 Igi recipients treated with anti-CD154 (n ϭ 4) (F) or naive 3-83 Igi recipients of C57BL/6 heart grafts treated with anti-CD154 (n ϭ 5) (Ⅺ) compared with rejecting memory 3-83 Igi recipients of C57BL/6 heart grafts treated with anti-CD154 (n ϭ 7) (ࡗ).
graft and anti-CD154 treatment compared with naive 3-83 Igi recipients receiving a C57BL/6 graft and anti-CD154 therapy ( Fig.  6a ; p ϭ 0.0036). A comparable increase in frequency of IgGsecreting 3-83 B cells was also observed in 3-83 Igi recipients that received only a C57BL/6 graft without any treatment. These data are consistent with the notion that rechallenge with C57BL/6 heart grafts results in the rapid expansion in the numbers of IgG-secreting alloreactive cells.
We next tested whether alloantibodies can synergize with functional memory 3-83 B cells to activate alloreactive T cells and induce allograft rejection in anti-CD154-treated BALB/c recipients. To this end, we tested whether sera transferred from presensitized 3-83 recipients could enhance the effects of transferred B cells also from presensitized 3-83 recipients. We observed that the transfer of sera from presensitized mice enhanced the ability of purified B cells to resist anti-CD154-mediated graft acceptance (Fig. 6b ) compared with half of grafts being rejected in BALB/c recipients only receiving memory B cells ( p ϭ 0.2681). Because of limiting amounts of sera from presensitized 3-83 Igi recipients, we also tested whether purified IgG2a mAbs from the 3-83 hybridoma had a similar ability to enhance the effects of B cells from presensitized 3-83 Igi recipients. The 3-83 mAb has the same dual specificity for allo-C57BL/6 and allo-C3H targets as does the 3-83 BCR expressed by 3-83 Igi mice (data not shown). We observed similar enhancement with a low dose of 3-83 IgG2a (0.30 mg/ mouse) that, by itself, did not cause rejection (Fig. 6b) .
Finally, we asked whether high concentrations of 3-83 IgG2a mAbs alone (0.50 mg/mouse) had the ability to induce C57BL/6 heart rejection in BALB/c recipients treated with anti-CD154. We observed that 3-83 IgG2a mAbs were able to induce the rejection of C57BL/6 hearts despite anti-CD154 therapy ( Fig. 6c ; MST, 17 days; p ϭ 0.0025). In contrast, all of the grafts survived long term (MST, Ͼ50 days) in BALB/c recipients receiving the same concentration of IgG2a isotype control mAbs along with anti-CD154 treatment. Additionally, the transfer of 3-83 IgG2a Abs into Rag Ϫ/Ϫ mice, which lack T and B lymphocytes, resulted in longterm graft survival in 80% in Rag Ϫ/Ϫ recipients (MST, 45 days; p ϭ 0.0025 compared with BALB/c recipients). These observations suggest that alloantibodies are able to mediate graft rejection in the presence of anti-CD154, and that this rejection is dependent on the presence of alloreactive T cells.
To determine the nature of the rejection process in BALB/c recipients receiving 3-83 IgG2a mAbs and anti-CD154, we first performed immunohistochemical analyses on heart graft tissues at 2 h posttransplantation and stained for the complement products C3d and C4. The rejected hearts had barely detectable staining for C3d and C4 (data not shown), consistent with the notion that 3-83 IgG2a-mediated cardiac allograft rejection is not due to complement deposition and vascular rejection. In contrast, we observed substantial CD4 ϩ and CD8 ϩ T cell infiltration in the C57BL/6 heart grafts from BALB/c recipients treated with 3-83 IgG2a mAbs and anti-CD154 compared with BALB/c recipients treated with IgG2a isotype control Abs and anti-CD154 therapy (Fig. 3b) . This histology was comparable to hearts rejected by presensitized 3-83 Igi recipients treated with anti-CD154 (Fig. 3a) .
Memory B cells and alloantibodies synergize to elicit the priming and proliferation of naive allospecific T cells
The presence of alloantibodies has been associated with both humoral as well as cellular rejection (37, 38) . We hypothesized that allograft rejection in presensitized 3-83 recipients treated with anti-CD154 was due to the activation of alloreactive T cells. Indeed, we observed a significantly increased frequency of C57BL/6-reactive cells producing IFN-␥ in whole splenocyte preparations from presensitized 3-83 Igi mice that had rejected the C57BL/6 allograft despite treatment with anti-CD154 compared with naive 3-83 Igi recipients treated with anti-CD154 ( Fig. 7a; p ϭ 0.0001 ). In contrast, a low to undetectable frequency of C57BL/6 reactive cells producing IFN-␥ was observed with splenocytes from naive 3-83 Igi recipients or naive 3-83 Igi recipients receiving C57BL/6 hearts and anti-CD154 (Fig. 7a) . We also repeated the experiment with purified T cells from rejected presensitized 3-83 Igi mice (Fig. 7a,  striped bars) , and we detected a comparable enhanced response to C57BL/6 Ags, relative to syngenic BALB/c Ags, as for whole spleen cells. These data confirmed that memory B cells are able to override the effects of anti-CD154 and facilitate the priming of alloreactive T cells.
These experiments that demonstrate the priming of alloreactive T cells in presensitized 3-83 recipients do not distinguish whether the alloreactive T cells arose from the memory cross-reactive T cell population or from naive C57BL/6-reactive T cells in presensitized 3-83 Igi recipients. To test whether functional memory B cells are able to facilitate the priming of naive alloreactive T cells in the presence of anti-CD154, we performed an adoptive transfer assay using CD4 ϩ T cells from naive D011.10 TCR Tg mice. Act-OVA Tg (C57BL/6 ϫ BALB/c)F 1 allografts were transplanted into naive or presensitized 3-83 Igi recipients treated with anti-CD154, along with 0.1 ϫ 10 7 CFSE-labeled D011.10 T cells. D011.10 CD4 T cells transferred into naive 3-83 Igi recipients had barely detectable proliferation, whereas cell proliferation was increased 18-fold when these Ag-specific T cells were transferred to untreated 3-83 Igi recipients that received Act-OVA F 1 heart grafts (Fig. 7c) . As expected, Ag-specific T cell proliferation was reduced 2-fold in naive 3-83 Igi recipients bearing Act-OVA F 1 heart grafts treated with anti-CD154. However, presensitized 3-83 Igi recipients of Act-OVA F 1 hearts treated in the presence of anti-CD154 therapy had a 2.5-fold increase in Ag-specific T cell proliferation in comparison to naive 3-83 Igi recipients. These data therefore support the conclusion that the presence of memory 3-83 B cells facilitates the CD154-independent activation of naive graftreactive T cells.
We also performed an IFN-␥ ELISPOT assay to detect primed alloreactive T cells in BALB/c recipients treated with 3-83 IgG2a mAbs along with anti-CD154. Purified T cells from the spleens of BALB/c recipients treated with anti-CD154 had an undetectable response to C57BL/6; however, T cells from spleens of BALB/c recipients treated with 3-83 IgG2a mAbs along with anti-CD154 had a higher frequency of primed IFN-␥-producing cells upon stimulation with C57BL/6 Ags (Fig. 7b) . These data collectively support the conclusion that alloantibodies are able to override the immunosuppressive effects of anti-CD154 to facilitate the priming of naive allospecific T cells and to induce allograft rejection.
Recent phenotypic characterization of memory B cells has revealed increased expression levels of both CD80 and CD86 on both murine and human memory B cells (39) (40). Additionally, it has been reported that signaling via CD40-CD154 results in the up-regulation of CD80 and CD86 on B cells, and that the enhanced FIGURE 6. Memory 3-83 Igi mice harbor an increased frequency of IgG-secreting cells, and memory B cells synergize with alloantibodies to overcome the tolerogenic effects of anti-CD154 treatment. a, Splenocytes were isolated from naive 3-83 Igi mice (n ϭ 11), naive 3-83 Igi recipients of C5BL/6 grafts and treated with anti-CD154 (n ϭ 5) (day 14 posttransplantation), naive 3-83 recipients of C57BL/6 grafts without treatment memory 3-83 Igi recipients at 60 days post-C3H transplantation (n ϭ 3), and memory 3-83 Igi of C57BL/6 grafts treated with anti-CD154 (n ϭ 9) (14 days posttransplantation C57BL/6 heart transplantation). The frequencies of IgG-secreting B cells were measured in a 3-83 idiotypic ELISPOT assay. b, Purified CD19 ϩ B cells (1.7-2.0 ϫ 10 7 ) from 3-83 Igi mice were isolated from spleens 60 days post-C3H transplant and adoptively transferred into naive BALB/c recipients of C57BL/6 heart grafts posttransplantation along with anti-CD154. Partial rejection of C57BL/6 heart grafts by BALB/c recipients following transfer of B cells from memory mice with anti-CD154 (n ϭ 10) (F) compared with complete rejection of BALB/c recipients injected with B cells plus 300 l of serum from memory mice with anti-CD154 (n ϭ 4) (छ), or injection of B cells with a low dose (300 g) of 3-83 IgG2a mAbs with anti-CD154 (n ϭ 4) (*), or injection of low dose 3-83 IgG2a mAbs with anti-CD154 (n ϭ 4) (ࡗ). c, 3-83 IgG2a mAbs prevent anti-CD154-mediated long-term graft survival. Long-term graft survival of C57BL/6 grafts in naive BALB/c recipients treated with anti-CD154 (n ϭ 5) (Ⅺ) and C57BL/6 grafts in Rag Ϫ/Ϫ BALB/c recipients treated with anti-CD154 and 0.5 mg of 3-83 IgG2a (n ϭ 5) (F) compared with rejecting C57BL/6 grafts in naive BALB/c recipients treated with anti-CD154 and 0.5 mg of 3-83 IgG2a (n ϭ 6) (ࡗ). Naive 3-83 Igi recipients of C57BL/6 grafts treated with 0.5 mg of isotype control IgG2a Abs with anti-CD154 were used as an isotype control (n ϭ 3) (OE). CD80/86 expression on memory B cells may bypass the need for CD40-CD154 interactions (41) . We therefore hypothesized that in our model, memory 3-83 B cells would stimulate allospecific T cell activation independently of CD40-CD154 interactions, but in a CD28-B7-dependent manner. Indeed, we observed that presensitized 3-83 recipients treated with the combination of anti-CD154 and CTLA4Ig prevented allograft rejection, confirming the necessity of CD28-B7 costimulation for allograft rejection by recipients harboring functional memory B cells (Fig. 8) .
Discussion
Memory B cell responses pose a barrier to achieving long-term allograft survival (42, 43) . During the past 10 years, the percentage of presensitized patients placed on the transplant waiting list has increased, and in 2003, 32% of the patients awaiting transplants were categorized as having HLA sensitivity, which was determined by their panel-reactive Ab scores (44) . Clinical studies have shown that HLA-sensitized patients have a poor transplant outcome prognosis (45, 46) . Present treatments for presensitized patients involve combinatorial therapies of plasmapheresis, highdose IVIg, and B cell-depleting Abs, all of which have unique advantages and disadvantages. Plasmapheresis results in a significant reduction of Ab titers (47) . However, plasmapheresis is a costly procedure that does not specifically target memory B cells and only transiently depletes anti-donor Abs without depleting the long-lived, Ab-secreting cells residing in the bone marrow. The second strategy of high-dose IVIg, which is comprised of serum from thousands of patients, has been the most successful at inducing a quiescent posttransplant immune response through a myriad of newly characterized pathways (48 -50) . The success of IVIg treatment has been overshadowed by its costliness and toxicity due to infusion-related complications when used at the recommended high dose. The third therapy involves the use of B cell antagonistic Abs such as rituximab, a mouse/human chimeric anti-CD20-depleting Ab that targets naive and effector B cells. However, rituximab treatment alone has been clinically unsuccessful in sensitized patients, and an important reason may be because memory and plasma B cells are resistant to anti-CD20 depletion (51, 52) . Thus, current B cell targeting strategies are costly, nonspecific, and inadequate in controlling the effector functions of the mature B cell population. Therefore, it is essential that we develop a better understanding of the biology of memory B cell populations so that novel approaches can be developed to control their functions.
The goal of our studies was to understand the properties of memory B cells during the induction of transplant tolerance. To achieve this goal, we reasoned that it was critical to develop an experimental model that isolated the effects of functional memory B cells, as a number of investigators have already demonstrated that memory T cells prevent the induction of tolerance due to their altered costimulatory requirements and heightened effector functions, compared with naive T cells. In conventional murine models of recipient sensitization with alloantigens, both B and T lymphocytes become activated and develop memory populations, making it difficult to distinguish the contributions of memory B cells from those of memory T cells.
We 7 T cells from donor-sensitized recipients were required to resist tolerance induction (15, 19) . We observed that the transfer of 1.7-2.0 ϫ 10 7 CD19 ϩ -depleted spleen cells from C3H-presensitized 3-83 Igi mice was insufficient to cause rejection of C57BL/6 heart grafts, but it was able to induce the rejection of C3H grafts in anti-CD154-treated BALB/c recipients. C3H-presensitized BALB/c mice, which is the background of 3-83 Igi mice and is presumed to harbor the same number of cross-reactive T cells as do the 3-83 Igi recipients, were unable to induce anti-CD154-resistant rejection. These observations collectively support the conclusion that the low frequencies of C57BL/6 cross-reactive memory T cells in presensitized 3-83 Igi recipients were insufficient to override the effects of anti-CD154 in our experimental model.
Two lines of evidence support a critical role for memory dualreactive 3-83 B cells in the induction of anti-CD154-resistant rejection. First, in the absence of dual-reactive 3-83 B cells, C3H-sensitized BALB/c mice, which are likely to have the same frequency of cross-reactive T cells as do the C3H-sensitized 3-83 Igi recipients, were unable to reject C57BL/6 heart grafts when treated with anti-CD154. Second, C57BL/6 hearts lacking K d , and thus lacking the Ag recognized by 3-83 B cells, were accepted by presensitized 3-83 Igi mice treated with anti-CD154. The activation of memory B cells then results in their differentiation into Ab-secreting cells, as illustrated by our observations of significantly higher frequencies of 3-83 IgG-secreting B cells in presensitized 3-83 Igi recipients rejecting C57BL/6 heart grafts despite anti-CD154 treatment, compared with these presensitized 3-83 Igi recipients before C57BL/6 heart transplant.
Memory 3-83 B cells were able to induce graft rejection in anti-CD154-treated BALB/c recipients but not in recipients also receiving CTLA4Ig, which blocks the CD28-B7 pathway. These observation are consistent with the higher expression of CD80 on memory B cells (39, 40) . Signaling via CD40-CD154 results in the up-regulation of CD80 and CD86 on B cells, and thus the enhanced CD80/86 expression on memory B cells may bypass the need for CD40-CD154 interactions (41) . Indeed, our observations collectively support the notion that the reactivation of memory B cells is less dependent on the CD40-CD154 pathway and more dependent on the CD28-B7 pathway. However, we presently do not know whether cognate interaction between memory B cells and T cells is necessary for the stimulation of naive alloreactive T cells that mediate graft rejection, or whether it is necessary for the reactivation of memory B cells into Ab-secreting cells. Our observation that 3-83 IgG2a mAbs or sera from presensitized mice, alone or in combination with memory 3-83 B cells, were able to induce graft rejection in anti-CD154-treated BALB/c recipients supports the latter possibility. Alloantibodies, including 3-83 mAbs, may directly bind to the vascular endothelium in the allograft to induce Ab-mediated vascular rejection and/or to synergize with effector T cells to induce allograft rejection (53, 54) . Alternatively, alloantibodies form immune complexes, which cause the enhanced alloantigen uptake via FcRs and/or complement receptors and optimum activation of APCs. These activated APCs may then up-regulate CD80/86 and activate T cells independently of CD40-CD154.
Allograft rejection by presensitized 3-83 Igi recipients or BALB/c recipients receiving high titers of 3-83 IgG2a and treated with anti-CD154 have pathologies consistent with acute T cellmediated rejection. These recipients harbor increased numbers of primed, IFN-␥-producing T cells specific for C57BL/6. Additionally, naive trace populations of graft-reactive CD4 ϩ T cells from naive D011.10 exhibited enhanced proliferation in presensitized 3-83 Igi recipients treated with anti-CD154, compared with naive 3-83 Igi recipients, confirming the ability of memory B cells and/or alloantibodies to facilitate the CD154-independent activation of naive T cells. Finally, the ability of CTLA4Ig to synergize with anti-CD154 to induce long-term graft acceptance is also consistent with the notion that the activation of naive alloreactive T cells is altered in recipients with memory B cells and/or Abs.
The priming of allospecific IFN-␥-producing cells in presensitized recipients treated with anti-CD154 was determined using an IFN-␥ ELISPOT assay in which allogeneic, syngeneic, or third party-irradiated spleen cells were used as stimulators. We note that under these assay conditions, it is likely that T cells recognize alloantigen primarily by the direct presentation pathway, although some indirect presentation is also likely to occur. In contrast, 3-83 B cells, alloantibodies, and immune complexes are more likely to enhance T cell activation through the indirect presentation pathway in vivo. We therefore theorize that the increased frequency of allospecific T cells observed in the ELISPOT assay reflects not only alloreactive T cells that were activated via the indirect pathway, but also alloreactive T cells that become activated by the direct pathway; these cells may have become activated by the process of epitope spreading (55) or by the semidirect pathway described by Lechler and colleagues (56) .
The ability of Abs to enhance T cell priming has been described in other models of autoimmunity, anti-tumor immunity, and protective immunity to infectious agents (57, 58) ; however, to our knowledge, our studies represent the first demonstration of this activity of alloantibodies in the context of immune reactivity to allografts. The contribution of Abs to priming of graft-reactive T cells contrasts with a previously described role of alloantibodies, binding to and activating graft vascular endothelium, and synergizing with primed effector T cells to induce allograft rejection (59) . Our novel findings raise a number of new questions. We do not know exactly how memory B cells or alloantibodies alter the activation requirements of naive allospecific T cells. We hypothesize that alloantibodies generate immune complexes that engage Fc or complement receptors and induce the activation of dendritic cells (59) , and studies to test this hypothesis are underway. Second, it is not clear whether memory B cells can also serve as APCs to directly activate allospecific T cells in a CD40-CD154-independent manner. Experimental approaches to visualize and track memory B cells are currently being developed to address this question. Collectively, these and ongoing studies will advance our understanding of the effector functions of memory B cells and provide insights into novel therapeutics for the treatment of sensitized transplant patients.
